Cerevance is focused on the development of cell-type specific treatments for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders
Cerevance is focused on the development of cell-type specific treatments for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders. Leveraging a vast collection of human brain tissue samples, the company identifies novel drug targets for CNS disorders using its proprietary NETSseq platform and advanced machine learning techniques.